An Information Portal to 111558 Biological Macromolecular Structures

ROC is found in 25 entries
  •   Chemical Component Summary   Hide
    Name (2S)-N-[(2S,3R)-4-[(2S,3S,4aS,8aS)-3-(tert-butylcarbamoyl)-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl]-3-hydroxy-1-phenyl-butan-2-yl]-2-(quinolin-2-ylcarbonylamino)butanediamide
    Identifiers N~1~-{(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl]-3-hydroxy-1-phenylbutan-2-yl}-N~2~-(quinolin-2-ylcarbonyl)-L-aspartamide
    Synonyms Fortovase
    SAQUINAVIR,RO 31-8959
    Formula C38 H50 N6 O5
    Molecular Weight 670.84 g/mol
    Type peptide-like
    Isomeric SMILES
    Sub-components QNC ASN HP0 NTB
  •   Drug Info: DrugBank Hide
    DrugBank ID DB01232   (Different stereochemistry)
    Name Saquinavir
    • approved
    • investigational
    Description An HIV protease inhibitor which acts as an analog of an HIV protease cleavage site. It is a highly specific inhibitor of HIV-1 and HIV-2 proteases. [PubChem]
    • Saquinavir Mesylate
    • SQV
    Brand names Invirase
    Affected organism Human Immunodeficiency Virus
    Indication For the treatment of HIV-1 with advanced immunodeficiency together with antiretroviral nucleoside analogues.
    Pharmacology Saquinavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Saquinavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs.
    Mechanism of action Saquinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.
    Route of administration oral
    Categories HIV Protease Inhibitors
    ATC-Code J05AE01
    AHFS-Code 08:18.08.08
    CAS number 127779-20-8
Ligand Image